Source: Taiwantrade | Updated: 19 August 2015
Held on July 22 and 23 in Taipei, the BioBusiness Asia (BBA) Conference was one of the major highlights of the 2015 Bio Taiwan exhibition.
Attended by the business, government and academic representatives of the Asia-Pacific biotech sector, the conference focused on the topics of precision medicine future healthcare, and biotech investment strategies.
On the development of precision medicine, the participants discussed ways to establish innovative cooperation links with international pharmaceutical companies, and the sharing of successful commercial models. Their discussions also touched on the opportunities and challenges facing the biotech industry and the sector's future.
Speaking at the opening ceremony of BBA, Bio Taiwan 2015 Chairman Johnsee Lee pointed out that U.S. President Barack Obama has put forth the Precision Medicine Initiative earlier this year believing that precision medicine is a necessary path forward for the world's bio-medical engineering industry.
The goal of precision medicine is to seek precise diagnosis methods and more effective drugs, and match them to develop the most economic and efficient medical therapies based on individual needs, Lee said. As different ethnic groups are endowed with different gene types, precision medicine is an industry that has different forms and needs in different areas. "This will be the advantage of Taiwan's biotech industry," Lee added.
Lee expressed his hope for Taiwan to gain a competitive position in precision medicine and find a direction for its future development in the Asia-Pacific market.
Chia Yi Lin (firstname.lastname@example.org)